FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Millham Brian 2. Date of Event Requiring Statement (MM/DD/YYYY)
8/8/2022 

3. Issuer Name and Ticker or Trading Symbol Salesforce, Inc. [CRM]
(Last)        (First)        (Middle)
415 MISSION STREET, 3RD FLOOR
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
President and COO /
(Street)
SAN FRANCISCO, CA 94105      
(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  5723  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)  3/22/2019 (1) 3/22/2025  Common Stock  8218  $118.04  D   
Non-qualified Stock Option (Right to Buy)  7/22/2019 (2) 7/22/2025  Common Stock  6608  $146.87  D   
Non-qualified Stock Option (Right to Buy)  3/22/2020 (3) 3/22/2026  Common Stock  15362  $161.50  D   
Restricted Stock Units  3/22/2020 (4) 3/22/2023  Common Stock  922  $0 (5) D   
Non-qualified Stock Option (Right to Buy)  4/22/2021 (6) 4/22/2027  Common Stock  54110  $154.14  D   
Restricted Stock Units  4/22/2021 (7) 4/22/2024  Common Stock  4583  $0 (5) D   
Non-qualified Stock Option (Right to Buy)  2/22/2022 (8) 2/22/2028  Common Stock  415009  $240.95  D   
Non-qualified Stock Option (Right to Buy)  3/22/2022 (9) 3/22/2028  Common Stock  96855  $215.17  D   
Restricted Stock Units  3/22/2022 (10) 3/22/2025  Common Stock  17980  $0 (5) D   
Non-qualified Stock Option (Right to Buy)  3/22/2023 (11) 3/22/2029  Common Stock  101121  $218.21  D   
Restricted Stock Units  3/22/2023 (12) 3/22/2026  Common Stock  27303  $0 (5) D   
Performance-Based Restricted Stock Units  5/15/2023 (13) 5/15/2023 (13) Common Stock  12592  $0 (14) D   

Explanation of Responses:
(1)  Option is exercisable and vests over four years at the rate of 25% on March 22, 2019, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(2)  Option is exercisable and vests over four years at the rate of 25% on July 22, 2019, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(3)  Option is exercisable and vests over four years at the rate of 25% on March 22, 2020, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(4)  These restricted stock units vest as to 25% of the original grant on March 22, 2020 and vest as to 1/16 of the original grant quarterly thereafter.
(5)  Restricted stock units convert to shares of Issuer common stock on a one-for-one basis.
(6)  Option is exercisable and vests over four years at the rate of 25% on April 22, 2021, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(7)  These restricted stock units vest as to 25% of the original grant on April 22, 2021, and vest as to 1/16 of the original grant quarterly thereafter.
(8)  Option is exercisable and vests over four years at the rate of 25% on February 22, 2022, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(9)  Option is exercisable and vests over four years at the rate of 25% on March 22, 2022, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(10)  These restricted stock units vest as to 25% of the original grant on March 22, 2022, and vest as to 1/16 of the original grant quarterly thereafter.
(11)  Option is exercisable and vests over four years at the rate of 25% on March 22, 2023, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
(12)  These restricted stock units vest as to 25% of the original grant on March 22, 2023, and vest as to 1/16 of the original grant quarterly thereafter.
(13)  The PRSUs will vest depending on Issuer's total shareholder return ("TSR") over the three-year period from the grant date (the "Performance Period"), relative to companies in the NASDAQ-100 Index as of the grant date (the "Index Group"). If Issuer's TSR over the Performance Period is at the 60th percentile when ranked against the Index Group TSRs, 100% of the target number of shares will vest. For every percentile by which Issuer's TSR ranking within the Index Group exceeds the 60th percentile, shares vesting will increase by 3 and 1/3%, up to a maximum payout of 200% of target if Issuer's TSR ranking is at the 99th percentile. For every percentile by which Issuer's TSR ranking within the Index Group is below the 60th percentile, shares vesting will decrease by 2 and 22/39%, with no payout if Issuer's TSR ranking is below the 30th percentile. If Issuer's absolute TSR over the Performance Period is negative, the number of shares vesting will not exceed 100% of target.
(14)  Each performance-based restricted stock unit, or PRSU, represents a contingent right to receive one share of Issuer common stock.

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Millham Brian
415 MISSION STREET
3RD FLOOR
SAN FRANCISCO, CA 94105


President and COO

Signatures
/s/ Scott Siamas, Attorney-in-Fact for Brian Millham 8/17/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Salesforce (NYSE:CRM)
過去 株価チャート
から 9 2022 まで 10 2022 Salesforceのチャートをもっと見るにはこちらをクリック
Salesforce (NYSE:CRM)
過去 株価チャート
から 10 2021 まで 10 2022 Salesforceのチャートをもっと見るにはこちらをクリック